Pipeline
Discover our pipeline and understand how our targeted approaches are being developed.
The Sitryx Product Engine
Driving discovery through the unique exploitation of cross-discipline expertise in drug development
Sitryx’s novel programmes
Sitryx is building a broad and differentiated pipeline of first- and best-in-class disease modifying therapeutics by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
Key proprietary programs
SYX-5219 – for the treatment of atopic dermatitis
SYX-5219 is a pyruvate kinase M2 activator which modulates B and T lymphocyte activity at the specific site of inflammation to reduce inflammation in the skin
SIT-052 – for the treatment of pulmonary fibrosis and COPD
Sitryx’s SIT-052 is a GLS1 inhibitor taken via an inhaled approach for the induction of the selective breakdown of senescent cells which contribute too ongoing fibrosis and inflammation in pulmonary fibrosis. Potential to be first in class treatment for patients with IPF, the inhaled approach is optimised for direct delivery into the lungs, maximising drug exposure.
SIT-033 – for the treatment of ulcerative colitis
SIT-033 is a SIK2 Inhibitor, which unlike early SIK inhibitors, is able to selectively target isozymes to maximise efficacy and therapeutic index in ulcerative colitis. Sitryx’s isozyme selective SIK2 inhibition offers the potential for sustained disease remission and improved safety profile in moderate to severe ulcerative colitis.
| Program | Hit-to-Lead | Lead Optimisation | Pre-clinical | Phase 1 | Partner |
|---|---|---|---|---|---|
| SYX-5219PKM2 | Atopic dermatitis | ||||
| SIT-052GLS1 | Pulmonary fibrosis | ||||
| SIT-033SIK2 | Inflammatory bowel disease | ||||
| Discovery pipeline | Multiple | ||||
| SYX-1042Itaconate mimetic | Autoimmune indications | ||||
| SIT-047OCM | Autoimmune indications | ||||
Patient perspectives
Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, has the potential to bring about better outcomes for patients and enable a broader population to achieve remission from chronic autoimmune and inflammatory disease.